[O2] Oral Session 2　Head and Neck Cancer
【E】

[O2-1] Trastuzumab deruxtecan in patients with HER2-expressing salivary gland carcinoma: Subgroup analysis of two Ph1 studies

^○Hideaki Bando¹, Ichiro Kinoshita², Shanu Modi³, Junji Tsurutani⁴, Yung-Jue Bang⁵, Hiroji Iwata⁶, Yuta Sato⁷, Shunsuke Nakatani⁷, Caleb Lee⁸, Masahiro Sugihara⁷, Yasuyuki Okuda⁷, Shunji Takahashi⁹ (1.National Cancer Center Hospital East, Chiba, Japan, 2.Hokkaido University Hospital, Hokkaido, Japan, 3.Memorial Sloan Kettering Cancer Center, New York, NY, United States, 4.Showa University, Tokyo, Japan, 5.Seoul National University Hospital, Seoul, Republic of Korea, 6.Aichi Cancer Center Hospital, Aichi, Japan, 7.Daiichi Sankyo Co., Ltd., Tokyo, Japan, 8.Daiichi Sankyo, Inc., Basking Ridge, NJ, United States, 9.The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan)